As of September 2026, a growing number of personal-injury lawsuits target the pharmaceutical manufacturers behind popular GLP-1 receptor agonists, including Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound. The core legal allegation is that manufacturers failed to adequately warn patients and prescribing clinicians about a potential risk of a rare and typically permanent eye disorder known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), often described as an “eye stroke.”

Following international regulatory updates in Europe, the United Kingdom, and Australia, along with an ongoing safety evaluation by the U.S. Food and Drug Administration (FDA), the mounting scrutiny surrounding GLP-1 medications serves as a critical reminder for prescribing practices, medical directors, and medspa operations: regulatory requirements, informed consent protocols, and patient safety signaling are constantly evolving.

What Is the Link Between GLP-1 Medications and NAION?

NAION occurs when blood flow to the optic nerve is suddenly restricted or cut off, resulting in rapid and typically permanent vision loss, usually in one eye, although the second eye can be affected later. Because there is no FDA-approved treatment to restore vision lost to NAION, any potential signal linking common medications to the condition warrants immediate clinical attention.

Recognized risk factors include diabetes, hypertension, obstructive sleep apnea, low blood pressure during sleep, and a small, crowded optic nerve head (the so-called “disc at risk”). Many of these conditions are common among patients who are prescribed GLP-1 medications, which is one reason the research is difficult to interpret.

1. Mass Eye and Ear Research & Observational Data

The debate surrounding GLP-1 drugs and NAION gained significant momentum after researchers at Harvard Medical School’s Mass Eye and Ear published an observational study in JAMA Ophthalmology in July 2024. Their findings indicated that patients prescribed semaglutide had a higher risk of a NAION diagnosis than matched patients on non-GLP-1 medications. The study was a retrospective, single-center review drawn from 16,827 patient records, and reported the following hazard ratios:

  • Type 2 Diabetes Cohort: Hazard ratio of 4.28 (95% CI, 1.62 to 11.29), or more than 4 times the risk.
  • Overweight/Obesity Cohort: Hazard ratio of 7.64 (95% CI, 2.21 to 26.36), or more than 7 times the risk.

The wide confidence intervals reflect a small number of NAION cases, and the study could not fully account for confounders such as diabetes severity, body mass index, steroid use, and prior eye surgery. The study showed an association; it did not establish that semaglutide causes NAION.

Subsequent large-scale retrospective studies and systematic reviews have yielded varied findings. A study of more than 174,000 patients found elevated risk emerging only after two or more years of use, while an analysis of roughly 1.2 million patients in the Military Health System found no increased risk.

While absolute incidence remains relatively low (NAION affects roughly 2.3 to 10.2 people per 100,000 each year in the general population, and the EMA estimated about one additional case per 10,000 person-years of semaglutide treatment in adults with type 2 diabetes), the rapid global expansion of GLP-1 prescribing turns even small statistical increases into significant public health considerations.

In September 2026, the American Academy of Ophthalmology (AAO) and the North American Neuro-Ophthalmology Society (NANOS) released a joint consensus statement concluding that semaglutide may roughly double the relative risk of NAION but that causation has not been established.

The statement does not recommend baseline eye exams solely to assess NAION risk before starting a GLP-1, recommends against automatic discontinuation after a NAION diagnosis in favor of shared decision-making, and advises that patients with prior NAION in one eye discuss the risk to the other eye before starting semaglutide.

2. Global Regulatory Action

International regulatory agencies have responded to these clinical observations:

  • European Medicines Agency (EMA): In June 2025, the EMA’s safety committee concluded that NAION is a very rare side effect of semaglutide (Ozempic, Rybelsus, and Wegovy), affecting up to 1 in 10,000 users, and required product information updates. The conclusion applies to semaglutide only, not the full GLP-1 class.
  • UK Medicines and Healthcare products Regulatory Agency (MHRA): In February 2026, advised prescribers to refer patients with sudden vision loss urgently to ophthalmology and to stop semaglutide if NAION is confirmed. Its review did not extend to other GLP-1 medicines.
  • Therapeutic Goods Administration (TGA – Australia): In July 2026, required NAION warnings across the GLP-1 receptor agonist class, including semaglutide, tirzepatide, dulaglutide, and liraglutide. Of the regulators listed here, only Australia has applied the warning class-wide.
  • U.S. FDA: Continues to evaluate the signal through its Sentinel Initiative to determine whether formal U.S. label revisions or warning updates are required. As of late September 2026, U.S. labeling for semaglutide and tirzepatide does not mention NAION, although those labels do warn about diabetic retinopathy complications.

Mounting Litigation and Failure-to-Warn Allegations

Dozens of federal and state lawsuits name drug manufacturers Novo Nordisk and Eli Lilly, alleging that companies knew or should have known about potential optic nerve risks and failed to properly update warning labels or inform prescribers. On December 15, 2025, the Judicial Panel on Multidistrict Litigation consolidated the federal NAION cases in the Eastern District of Pennsylvania as MDL No. 3163, before Judge Karen S. Marston, who also presides over the separate GLP-1 gastrointestinal-injury litigation (MDL No. 3094).

The consolidation order covered claims involving Ozempic, Wegovy, Saxenda, and Trulicity, and litigation trackers report that the MDL has since grown to more than 200 pending cases. Novo Nordisk has said the lawsuits lack merit. While litigation does not establish medical causation on its own, it highlights a major legal vulnerability for healthcare businesses: the gap between emerging medical literature and clinical practice protocols.

This gap matters because of the learned intermediary doctrine, which in most states allows a drug manufacturer to satisfy its duty to warn by warning the prescriber rather than the patient. Failure-to-warn cases therefore routinely examine what the prescriber knew, what the prescriber told the patient, and whether a different warning would have changed the prescribing decision. A clinic’s charts, consent forms, and prescriber testimony can become central evidence even when the clinic is not a named defendant.

When a potential adverse event becomes widely publicized or subject to regulatory safety warnings, plaintiffs’ attorneys routinely inspect whether treating clinics:

  1. Conducted adequate baseline risk screenings before prescribing.
  2. Informed the patient of rare but severe potential adverse outcomes.
  3. Responded appropriately when patients reported early or sudden visual changes.

Legal, Regulatory, and Malpractice Exposure for Medical Practices

For medical spas, wellness clinics, weight-loss centers, and telehealth platforms offering compounded or brand-name GLP-1 regimens, rising scrutiny creates distinct practice management risks:

  • Informed Consent Deficiencies: Utilizing outdated or standard weight-loss consent forms that omit emerging optic risks can expose clinics and supervising physicians to “failure to inform” claims if a patient experiences sudden visual changes. Because U.S. labeling does not yet mention NAION, the FDA label alone is not a reliable guide to what patients should be told.
  • Standard-of-Care & Board Complaints: Medical boards expect prescribing clinicians—and supervising medical directors—to remain aware of emerging drug safety warnings. Failing to screen high-risk patients (e.g., those with pre-existing optic nerve conditions, severe vascular disease, or sleep apnea) can lead to board inquiries following an adverse event.
  • Compounded GLP-1 Sourcing Risks: Practices utilizing custom compounded semaglutide or tirzepatide face double exposure. If a patient experiences an adverse visual event, the clinic may have to defend both the prescribing decision and its choice of compounding pharmacy, including that pharmacy’s API sourcing, sterility, and labeling practices. Compounded products also do not carry manufacturer labeling, which leaves the clinic’s own consent and counseling materials as the main record of what the patient was told.
  • Narrowing Legal Basis for Compounding: FDA declared the tirzepatide and semaglutide shortages resolved, ending the shortage-based allowance for compounded copies. Section 503A pharmacies generally may not regularly compound drugs that are essentially copies of an approved product unless the prescriber documents a clinically significant difference for the individual patient. A practice still prescribing compounded GLP-1s after an adverse event should expect scrutiny of the legal basis for each prescription.
  • Malpractice Insurance Coverage: Insurance providers closely monitor mass-tort litigation and regulatory safety signals. Incomplete charting or prescribing GLP-1s without documented baseline safety protocols can complicate professional liability defense.

Practical Action Steps for Prescribing Clinics and Medical Directors

To maintain clinical quality, uphold patient safety, and minimize legal exposure, healthcare providers and practice managers should implement the following steps:

  1. Update Informed Consent Forms Immediately: Ensure GLP-1 intake paperwork explicitly discloses potential, rare ocular side effects—including sudden vision changes or NAION—alongside standard gastrointestinal, thyroid, and diabetic retinopathy risk disclosures. Document the risk discussion in the chart, not only on the signed form.
  2. Refine Intake and Baseline Screening Protocols: Intake should capture vascular conditions, hypertension, low blood pressure during sleep, obstructive sleep apnea (and whether it is treated), microvascular complications, and any prior NAION or other optic nerve disease. A “disc at risk” can only be identified on an eye exam, so intake forms cannot screen for it directly. Current AAO and NANOS guidance does not call for routine baseline eye exams solely to assess NAION risk, but patients with diabetes should stay current on diabetic eye exams, and patients with prior NAION in one eye warrant a documented risk discussion before starting semaglutide.
  3. Establish Clear Patient Instructions for Visual Changes: Advise patients in writing to seek same-day ophthalmic evaluation and contact their prescriber before taking another dose if they experience sudden, painless loss or dimming of vision, dark spots, or blurred field of vision. Whether to stop the medication after NAION is confirmed should be a documented prescriber decision.
  4. Audit Off-Label and Direct-to-Consumer Marketing Claims: Review practice websites, social media posts, and landing pages. Eliminate statements promising that GLP-1 therapies carry “no serious side effects” or depicting them as risk-free weight-loss solutions. Also remove claims that compounded products are the same as, or generic versions of, Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded drugs are not FDA-approved.
  5. Review Supplier and Compounding Compliance: Ensure all sourcing partners operate in full compliance with state board and FDA regulations, providing clear certificates of analysis (CoAs) for all active pharmaceutical ingredients (APIs). Confirm and document the legal basis for each compounded GLP-1 order in light of the post-shortage restrictions described above.
  6. Report and Track Adverse Events: Report suspected NAION cases to FDA, notify the compounding pharmacy when a compounded product is involved, and keep an internal adverse-event log that the medical director reviews.

This article is provided for informational purposes only and does not constitute legal or medical advice. Healthcare practices and medical directors seeking guidance on GLP-1 compliance, informed consent documentation, or healthcare regulatory risk management should consult a qualified healthcare attorney.

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.